With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Never skip a beat on new music and news. Straight to your inbox, 3x a week. Donate to KCRW to support this cultural hub for music discovery, in-depth journalism, community storytelling, and free ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results